Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.64 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | DDO | Q99489 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | IAPP | P10997 | 2/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990467 | 0.86 | GABRA1 (0.56) | GABRA1GABRB2ALDH1A1LMNAIAPP | |
| SCHEMBL3593817 | 0.86 | GABRA1 (0.56) | GABRA1GABRB2DAODDOALDH1A1 | |
| SCHEMBL3238496 | 0.82 | GABRA1 (0.57) | GABRA1GABRB2DAODDOALDH1A1 | |
| SCHEMBL27807373 | 0.80 | HMGB1 (0.56) | GABRA1GABRB2ALDH1A1HMGB1CXCL12 | |
| SCHEMBL11220048 | 0.80 | GABRA1 (0.48) | GABRA1GABRB2ALDH1A1LMNA | |
| SCHEMBL199730 | 0.79 | GABRA1 (1.00) | GABRA1GABRB2DAODDOIAPP | |
| SCHEMBL3584443 | 0.78 | GABRA1 (0.56) | GABRA1GABRB2DAODDOALDH1A1 | |
| SCHEMBL26253878 | 0.78 | GABRA1 (0.54) | GABRA1GABRB2DAODDOALDH1A1 | |
| SCHEMBL3954604 | 0.78 | GABRA1 (0.50) | GABRA1GABRB2DAODDOALDH1A1 | |
| SCHEMBL10337449 | 0.77 | GABRA1 (0.48) | GABRA1GABRB2LMNAHMGB1CXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514520-B2 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080091050-A1 | Process For Producing Phosphonitrilic Acid Ester | ASAHI KASEI CHEMICAL CORPORATION (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070060739-A1 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| CN-1798753-A | Process for producing phosphonitrilic acid ester | ASAHI CHEMICAL CORP (JP) | 2006-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091050-A1 | Process For Producing Phosphonitrilic Acid Ester | PHOSPHO1, GNPAT, SELENOI | GABRA1 2466/4885GABRB2 2320/4885DAO 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.